|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
A16 AB05
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:chemical_formula
|
C22 H30 F2 N2 O4 S
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:condition
|
Gaucher disease type 1
Gaucher disease type 3
|
|
gptkbp:contraindication
|
severe liver impairment
concurrent use of strong CYP2 D6 inhibitors
|
|
gptkbp:dosage_form
|
100 mg
200 mg
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP2 D6 inhibitors
CYP2 D6 substrates
|
|
gptkbp:effective_date
|
2014-08-01
|
|
gptkbp:financial_support
|
available through manufacturer
|
|
gptkbp:form
|
gptkb:capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cerdelga
|
|
gptkbp:ingredients
|
eliglustat
|
|
gptkbp:invention
|
2029-12-31
|
|
gptkbp:is_monitored_by
|
cardiac function
liver function tests
blood counts
|
|
gptkbp:label
|
includes patient information
includes prescribing information
|
|
gptkbp:manufacturer
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
substrate for CYP2 D6
|
|
gptkbp:ndc
|
12345-6789
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:patient_population
|
adults
children over 2 years old
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
recommended for Gaucher disease
|
|
gptkbp:research
|
post-marketing studies
ongoing clinical trials
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
Pregnancy Category C
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
may be covered
|
|
gptkbp:used_for
|
gptkb:disease
|
|
gptkbp:weight
|
442.55 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Sanofi_Aventis
|
|
gptkbp:bfsLayer
|
5
|